Table 1.
Baseline characteristics of the participants.
| Characteristics | Vitamin D (N = 40) | Placebo (N = 40) |
|---|---|---|
| Age (years) a | 59.95 ± 5.81 | 58.33 ± 6.25 |
| Age at menopause a | 48.5 ± 5.35 | 49.5 ± 4.24 |
| Body mass index (kg/m2) a | 24.14 ± 3.92 | 24.63 ± 4.24 |
| Active sexual activity b | 19 (51.35%) | 18 (48.65%) |
| Nulliparous b | 7 (17.5%) | 9 (22.5%) |
| Having underlying medical diseases | 20 (50%) | 26 (65%) |
| Smoking history b | 2 (5%) | 0 (0%) |
| Alcohol drinking b | 2 (5%) | 0 (%) |
| Regular exercise b | 22 (44%) | 28 (56%) |
| Vaginal maturation index a | 10.33 ± 19.00 | 18.56 ± 27.99 |
| Vaginal pH a | 7.55 ± 1.02 | 7.51 ± 0.94 |
| VAS of VVA symptoms a | 7.21 ± 2.20 | 6.48 ± 2.28 |
| Serum 25(OH)vitamin D level (ng/mL) a | 24.98 ± 8.25 | 23.28 ± 7.53 |
Notes: a Data expressed as mean ± standard deviation (SD), b data expressed as a percentage. VAS—visual analog scale; VVA—vulvovaginal atrophy.